For research use only. Not for therapeutic Use.
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research[1].
Vibostolimab binds to TIGIT and blocks the interaction between TIGIT and its ligands (CD112 and CD155), activating T lymphocytes which help to destroy tumor cells[1].
| Catalog Number | I043193 |
| CAS Number | 2231305-30-7 |
| Purity | ≥95% |
| Reference | [1]. Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33(2):169-180. |
